Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiR-126 prevents hypoxic HUVEC cellular injury through targeting TRAF6 expression.

Cardiovascular journal of Africa·2026
Same author

MicroRNA-21 Protects Hypoxic-Induced Cardiomyocytes Injury by Targeting Smad-7.

Cells·2025
Same author

Detection of diversity of fetal heart function in pregnancy-induced hypertension patients by ultrasonography in Aljouf Region, Saudi Arabia.

African health sciences·2025
Same author

Impact of microRNAs on cardiovascular diseases and aging.

The Journal of international medical research·2024
Same author

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice.

Journal of cardiovascular development and disease·2023
Same author

Neutrophil to high-density lipoprotein cholesterol ratio as the risk mark in patients with type 2 diabetes combined with acute coronary syndrome: a cross-sectional study.

Scientific reports·2023
Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026
Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026
Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026
Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026
Same journal

Biomarkers in heart failure.

Advances in clinical chemistry·2026
Same journal

Advances in small extracellular vesicle analysis.

Advances in clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Cardiovascular disease and miRNA.

Md Sayed Ali Sheikh1, Ummeb Salma2

  • 1Internal Medicine Department, College of Medicine, Jouf University, Jouf, Saudi Arabia.

Advances in Clinical Chemistry
|June 23, 2026
PubMed
Summary
This summary is machine-generated.

MicroRNAs (miRNAs) are key regulators in cardiovascular disease (CVD). Dysregulated miRNAs show potential as diagnostic biomarkers and therapeutic targets for improving CVD outcomes.

Keywords:
BiomarkersCardiovascular diseaseDiagnosisMicrornaPrognosisTherapeutic

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Related Experiment Videos

Last Updated: Jun 25, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Cardiovascular disease (CVD) presents a significant global health challenge, driving morbidity, mortality, and healthcare costs.
  • Current CVD management requires improved non-invasive biomarkers for early detection and novel therapeutics for better patient outcomes.

Purpose of the Study:

  • To review the molecular and clinical significance of microRNAs (miRNAs) in cardiovascular diseases (CVD).
  • To explore the potential of circulating miRNAs as diagnostic and prognostic biomarkers for CVD.
  • To discuss miRNAs as prospective therapeutic targets in CVD management.

Main Methods:

  • Literature review of studies investigating microRNAs in cardiovascular disease.
  • Analysis of research on miRNA expression profiles in conditions like stable coronary artery disease (CAD) and acute coronary syndrome (ACS).
  • Synthesis of findings on the diagnostic, prognostic, and therapeutic roles of miRNAs in CVD.

Main Results:

  • MicroRNA dysregulation is implicated in the pathogenesis of various CVDs.
  • Specific circulating miRNAs exhibit potential as reliable biomarkers for CVD diagnosis and prognosis.
  • miRNA expression profiles offer promising avenues for novel therapeutic strategies in CVD.

Conclusions:

  • MicroRNAs play crucial roles in the molecular mechanisms underlying cardiovascular diseases.
  • Circulating miRNAs represent a valuable resource for non-invasive CVD biomarker discovery.
  • Targeting miRNAs holds significant therapeutic potential for managing and treating CVD.